4SC and Sanwa Kagaku Kenkyusho (SKK) completed their research collaboration in the field of diabetes, which was started in January 2005. The successful completion triggers another significant payment from SKK, which is now responsible for further R&D. 4SC continues to participate in future potential milestone and royalty payments.
Under the terms of the agreement, 4SC applied its virtual high-throughput screening technology, 4SCan®, followed by biological screening experiments to identify active agents against specific targets provided by SKK. In a second step 4SC optimized these hits chemically with respect to certain properties like potency, selectivity, and their in vitro ADMET profile.